$HPE

Benzinga

Benzinga reports several Wall Street analyst rating changes. Loop Capital upgraded Hewlett Packard Enterprise (HPE) to Buy and raised its target to $75 from $23. Raymond James upgraded Atlas Energy Solutions (AESI) to Outperform with a $25 target. Deutsche Bank upgraded Macerich (MAC) to Buy, target $27. Wedbush upgraded Abivax (ABVX) to Neutral, cutting target to $90. JP Morgan upgraded Eagle Materials (EXP) to Neutral with a $225 target.

Original reporting
Published Jun 3, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Benzinga — source image
Decision brief

The 30-second read

$HPEBullishMed
01

Why it matters

These are sentiment/positioning catalysts rather than fundamental disclosures; the most tradable element is the direction of the rating change and whether the price target moved up or down.

02

Market read

Rating changes can drive short-term flows and options positioning, but the lack of new operational data limits conviction.

03

What to watch

The article provides targets and rating moves but not the underlying thesis changes; traders should verify whether the target change reflects updated assumptions or merely valuation recalibration.

Relevance 6/10Novelty 6/10Timing: during/after today’s session as analysts’ rating changes circulate

Background

The piece is a Benzinga roundup of Wall Street analyst rating changes, listing upgrades/downgrades and associated price target revisions for several large US-listed companies.

Company-level read

Ticker impact

$HPEBullishMedium confidence
Context

Hewlett Packard Enterprise was upgraded by Loop Capital from Hold to Buy with a raised price target to $75.

Expected impact

Mild-to-moderate upside bias versus peers, with follow-through dependent on broader market/earnings expectations.

Evidence & confidence

The article provides a clear rating change and target raise, but no new company-specific fundamental datapoint beyond analyst view.

$AESIBullishMedium confidence
Context

Atlas Energy Solutions was upgraded by Raymond James from Market Perform to Outperform with a new $25 price target.

Expected impact

Potential short-term positive drift if positioning follows analyst changes.

Evidence & confidence

The news is directly about the stock’s analyst stance, but the piece lacks new operational or financial results.

$MACBullishMedium confidence
Context

Macerich was upgraded by Deutsche Bank from Hold to Buy and its price target was raised to $27.

Expected impact

Moderate upside bias; magnitude likely smaller than for highly volatile catalysts.

Evidence & confidence

Clear analyst action is provided, but no new fundamentals or guidance are disclosed in the article.

$ABVXNeutralMedium confidence
Context

Abivax was upgraded by Wedbush from Underperform to Neutral while cutting the price target from $110 to $90.

Expected impact

Likely limited upside; could trade range-bound as investors weigh upgrade vs target cut.

Evidence & confidence

The article contains both an upgrade and a target reduction, making direction less certain.

$EXPNeutralMedium confidence
Context

Eagle Materials was upgraded by JP Morgan from Underweight to Neutral with a $225 price target.

Expected impact

Slight positive bias, but less aggressive than a Buy/Outperform call.

Evidence & confidence

The rating change is constructive, yet the target update is not accompanied by new company-specific fundamentals.

Market effects

Broad read-across is limited: these are single-name analyst rating changes across diversified industries (tech/energy/REIT/materials/biopharma).

Primarily US-listed equities sentiment; no clear regional macro linkage.

Low—no cross-border deal/regulatory catalyst described.

Counterpoint

Analyst upgrades/downgrades can be slow to translate into fundamentals; without new earnings/guidance, price may mean-revert after initial positioning flows.

Key entities

  • Loop Capital

    Upgraded HPE from Hold to Buy and raised its price target to $75.

  • Raymond James

    Upgraded AESI from Market Perform to Outperform with a $25 price target.

  • Deutsche Bank

    Upgraded MAC from Hold to Buy and raised its price target to $27.

  • Wedbush

    Upgraded ABVX from Underperform to Neutral but cut its price target to $90.

  • JP Morgan

    Upgraded EXP from Underweight to Neutral with a $225 price target.

Related articles

$MACMedAI 8/10

Macerich Company: Macerich Announces Pricing of Upsized Offering of $675 Million Exchangeable Senior Notes due 2031

Macerich (NYSE: MAC) priced an upsized $675 million offering of 2.25% exchangeable senior notes due 2031, up from $600 million. The notes settle Aug. 11, 2026, pay 2.25% semiannually, mature Aug. 15, 2031, and are exchangeable into MAC shares at an initial rate of 35.4761 shares per $1,000 principal. Net proceeds are about $659.1 million.

$MACMed

The Macerich Company Q2 2026 Earnings Call Summary

Macerich reported progress on its Path Forward 3.0 plan, with leasing completion at 88% versus a midyear 85% target. Management reiterated 2026 go-forward portfolio NOI growth of at least 3%, accelerating to 3.5%+ in 2H, and expects >8% NOI growth in 2027-28 as a $140 million SNO pipeline contributes rent. Net debt/adj. EBITDA improved to 7.3x. The company plans $372 million of unsettled forward equity for acquisitions and noted a $76 million loan default at 29th Street.

$MACMed

Mall Giant Macerich Narrows Losses in Q2 Amid Stronger Leasing

Macerich (a mall REIT) reported Q2 leased occupancy of 94% (up from 92% a year earlier) after signing about 1.3 million sq ft of new and renewal leases. Lease revenue was $233.4M and total revenue $249.7M. Adjusted FFO was $100.4M. Net loss narrowed to $27.1M from nearly $41M, helped by asset sales. Go-forward NOI rose 3.8% and the company cited $1.2B liquidity.

$ABVXMedAI 8/10

ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears

Abivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.

$HPEMed

Exclusive: HPE Guarantees Deal Quotes Below $1M Amid Rising Memory Prices

HPE says it has changed contractual terms to guarantee partner price quotes for compute, storage and GreenLake Flex deals under $1 million net, so quoted prices will be what customers pay even if memory prices rise and shipments are delayed. HPE cites partner feedback and notes competitors have repriced on shipment; NAND Research expects DRAM prices to keep rising into 2027-28.

$MACMed

MACERICH CO (MAC): Results of Operations and Financial Condition

MACERICH CO (MAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2-exhibit991.htm EX-99.1 2026 Q2- Exhibit 99.1 Exhibit 99.1 Earnings Results & Supplemental Information For the Three and Six Months Ended June 30, 2026 The Macerich Company Earnings Results & Supplemental Information For the Three and Six Months Ended June 30, 20